Factors that influence oral bioavailability; A cathepsin K inhibitor for human studies

  • Daniel F. Veber
Part of the Advances in Experimental Medicine and Biology book series (volume 611)


Oral Bioavailability Rotatable Bond Polar Surface Area Methyl Substitution Rotational Freedom 



I am thankful for the continuing valued discussions on these topics with Dr. Kenneth D. Kopple.


  1. 1.
    Lipinski, C. A. Pharmacol Toxicol. Methods. 44, 235–249 (2000).CrossRefGoogle Scholar
  2. 2.
    Veber, D. F., Johnson, S. R., Cheng, H-Y., Smith, B. R., Ward, K. W., and Kopple, K. D. J. Med. Chem. 45, 2615–2623 (2002).CrossRefGoogle Scholar
  3. 3.
    Kwan, K. C., Drug Metab. and Disp. 25, 1329–1336 (1997).Google Scholar
  4. 4.
    Yamashita, D. S. and Dodds, R. A., Curr. Pharm. Design. 6, 1–24 (2000).CrossRefGoogle Scholar
  5. 5.
    Veber, D. F. et. al., Peptides 2000: Proc. 26th Eur. Pept. Symp; Martinez, J. and Fehrentz, J.-A., Eds.; Editions EDK; Paris, 2000; pp113–114.Google Scholar
  6. 6.
    Yamashita, D. S. et. al.J. Med. Chem. 49, 1597–1612 (2006).CrossRefGoogle Scholar
  7. 7.
    Kumar, S. et. al. Bone. 40, 122–131 (2007).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Daniel F. Veber
    • 1
  1. 1.Drug Discovery ConsultantAmbler

Personalised recommendations